Search

Astellas Pharma Inc.
  • Top MenuAbout
    Corporate Information
    Europe is a global centre of excellence in healthcare and Astellas is committed to supporting Europe, the Middle East and Africa (EMEA)…
    Read More
    • Philosophy
    • Vision & Strategy
    • Group Code of Conduct
    • Corporate Information
    • Policies & Position Statements
    • Medical Education
      • Support for Medical Education
      • Congress: Grants to HCOs
  • Top MenuTherapy areas
    • BETMIGA ™
    • EVRENZO™
    • MYCAMINE™
    • PADCEV™
    • VESICARE™
    • VESOMNI™
    • XOSPATA™
  • Top MenuProducts
  • Top MenuInnovation
    Clinical Trials
    Astellas has established a website to disclose information obtained from Astellas-sponsored clinical trials…
    Read More
    • R & D
      • Clinical Trials
      • Approach
      • Ethics & Principles
    • Investigator Sponsored Research
  • Top MenuSustainability
    Access to Health
    Advances continue to be made in technology and medicine that address unmet medical needs. However, there still remain barriers for many people…
    Read More
    • CSR-Based Management
      • ISO26000
      • Materiality
    • CSR Activities in Five Fields
      • Society
      • Environment
      • Employees
      • Ethics & Compliance
    • Access to Health
      • ACTION ON FISTULA™
    • Transparency
    • Modern Slavery Act
    • Global Sustainability Policy
  • Top MenuNews
    Media Contacts
    The Astellas EMEA Corporate Communications team will respond to calls and emails from journalists…
    Read More
    • News
    • Media Contacts
    • Social Media Code of Conduct

Common header menu

  • CAREERS
  • CONTACT US
  • WORLDWIDE
  • NETHERLANDS
  • WORLDWIDE - NETHERLANDS
  1. Home
  2. Products

Products

Transplantatie

  • ADVAGRAF™
      – Bijsluiter ADVAGRAF™ 0,5, 1, 3 & 5 mg
      – SmPC ADVAGRAF™ 0,5, 1, 3 & 5 mg
     
  • PROGRAFT™
      – Bijsluiter PROGRAFT™-caps
      – Bijsluiter PROGRAFT™-conc
      – SmPC PROGRAFT™-caps
      – SmPC PROGRAFT™-conc
 


Anti-infectiva

  • MYCAMINE™
      – Bijsluiter MYCAMINE™ 50 & 100 mg
      – SmPC MYCAMINE™ 50 & 100 mg

    Additioneel risicominimalisatie materiaal
    Checklist voor voorschrijvers micafungine

Oncologie

  • PADCEV™
      – Bijsluiter PADCEV™ poeder voor concentraat voor oplossing voor infusie
      – SmPC PADCEV™ poeder voor concentraat voor oplossing voor infusie

    Additioneel risicominimalisatie materiaal
    Patiënteninformatiepakket
     
  • XOSPATA™
      – Bijsluiter XOSPATA™ filmomhulde tabletten
      – SmPC XOSPATA™ filmomhulde tabletten

    Additioneel risicominimalisatie materiaal
    Waarschuwingskaart voor de patiënt
    Voorlichtingsbrochure voor voorschrijvers
     
  • XTANDI™
      – Bijsluiter XTANDI™
      – SmPC XTANDI™
     

Urologie

  • BETMIGA™
      – Bijsluiter BETMIGA™
      – SmPC BETMIGA™
     
  • VESICARE™
      – Bijsluiter VESICARE™ 5 & 10mg
      – SmPC VESICARE™ 5 & 10mg
     
  • VESOMNI™
      – Bijsluiter VESOMNI™
      – SmPC VESOMNI™


Nefrologie

  • EVRENZO™
      – Bijsluiter EVRENZO™
      – SmPC EVRENZO™

 

 

NON_2021_0057_NL_DEC

  • Linkedin
  • Twitter
LogoSolgan

Follow us on social media

linkedin_icon twitter_icon

Bottom footer menu

  • SITE MAP
  • PRIVACY STATEMENT
  • TERMS OF USE
  • CONTACT US
  • COOKIE BELEID
  • MODERN SLAVERY ACT
© 2021-2023 Astellas Pharma B.V.

Update de cookievoorkeur